User:MicHuynh/Embryonal rhabdomyosarcoma

Prognosis
In a 2020 case study of 464 adolescents aged 0-19 years diagnosed with RMS between 1988 to 2016, it was found that children who were diagnosed between ages 5-9 years had the most promising prognosis. In contrast, infants less than 1 years old had the worst outcome, which may be associated to the lower doses of chemotherapy and radiotherapy administered and naive immune system.

In two different studies, none of the subjects with the MYOD1 mutation survived. Tumors due to this mutation commonly manifest in the head and neck area and cause the mutated protein to behave like an oncogene.

Multidisciplinary aggressive treatment of RMS has promising results, with 90% relapse-free survival rates for those with low-risk

In the recent years, there has been a shift to use molecular classification over histological classification as histology alone does not predict the fusion type of rhabdomyosarcoma.